@article{PrifertStrengKrempletal.2013,
  author    = {Prifert, Christiane and Streng, Andrea and Krempl, Christine D. and Liese, Johannes and Weissbrich, Benedikt},
  title     = {Novel Respiratory Syncytial Virus A Genotype, Germany, 2011-2012},
  series = {Emerging Infectious Diseases},
  volume    = {19},
  journal   = {Emerging Infectious Diseases},
  number    = {6},
  doi       = {10.3201/eid1906.121582},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-129041},
  pages     = {1029-1030},
  year      = {2013},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{StrengGroteCarretal.2013,
  author    = {Streng, Andrea and Grote, Veit and Carr, David and Hagemann, Christine and Liese, Johannes G.},
  title     = {Varicella routine vaccination and the effects on varicella epidemiology - results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011},
  series = {BMC Infectious Diseases},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/1471-2334-13-303},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96297},
  year      = {2013},
  abstract  = {Background In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated. Methods Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated. Results Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38\%, 51\%, 53\%, 53\%, 66\% and 68\%); second-dose coverage reached 59\% in the 2011 survey. A monthly mean of 82 (62\%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67\% in two steps, from 6.6 (95\%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95\%CI 3.9-4.6) in 2007/08 and 4.0 (95\%CI 3.6-4.3) in 2008/09, and further to 2.3 (95\%CI 2.0-2.6) in 2009/10 and 2.2 (95\%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95\%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95\%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95\%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5\%) with neurological complications and one (0.6\%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age. Conclusions Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage.},
  language  = {en}
}
@article{PrelogZlamyKofleretal.2013,
  author    = {Prelog, Martina and Zlamy, Manuela and Kofler, Sabine and Orth, Dorothea and W{\"u}rzner, Reinhard and Heinz-Erian, Peter and Streng, Andrea},
  title     = {The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections},
  series = {BMC Infectious Diseases},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/1471-2334-13-112},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96147},
  year      = {2013},
  abstract  = {Background The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). Methods The retrospective evaluation (2002-2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002-2005) was compared with the recommended and early funded (2006-2007) and the funded (2008-2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons. Results In 1,532 children with RV-GE, a significant reduction by 73.9\% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0-11 months (by 87.8\%), 6-10 years (by 84.2\%) and 11-18 years (88.9\%). In the funded vaccination period, a reduction by 71.9\% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7\% in the funded vaccination period. The reduction of direct costs for patients (by 86.9\%) and accompanying persons (86.2\%) was most pronounced in the age group 0-11 months. Conclusions UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.},
  language  = {en}
}